| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
|
Naso, Michael F.
|
|
2017
|
31 |
4 |
p. 317-334
|
artikel
|
| 2 |
A ‘Global Reference’ Comparator for Biosimilar Development
|
Webster, Christopher J.
|
|
2017
|
31 |
4 |
p. 279-286
|
artikel
|
| 3 |
Cell-Based Therapies with T Regulatory Cells
|
Gliwiński, Mateusz
|
|
2017
|
31 |
4 |
p. 335-347
|
artikel
|
| 4 |
Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis
|
Park, Won
|
|
2017
|
31 |
4 |
p. 369-377
|
artikel
|
| 5 |
Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial
|
Yoo, Dae Hyun
|
|
2017
|
31 |
4 |
p. 357-367
|
artikel
|
| 6 |
Erratum to: A ‘Global Reference’ Comparator for Biosimilar Development
|
Webster, Christopher J.
|
|
2017
|
31 |
4 |
p. 287
|
artikel
|
| 7 |
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
|
Strand, Vibeke
|
|
2017
|
31 |
4 |
p. 299-316
|
artikel
|
| 8 |
LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects
|
Lee, Heechan
|
|
2017
|
31 |
4 |
p. 349-355
|
artikel
|
| 9 |
Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab
|
Reid, Ian R.
|
|
2017
|
31 |
4 |
p. 289-297
|
artikel
|
Tijdschrift beschrijving